Stefan Oelrich, president of Bayer’s pharmaceutical division and newly appointed head of the EU’s pharmaceutical lobby EFPIA, pointed out the urgent need for capital market reform to support biotech development in Europe.
“We need the equivalent of a Nasdaq in Europe where we can raise capital for biotech. Because biotech is not just about government finance,” Oelrich said during a press conference last week.
